N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction?

Research output: Contribution to journalArticle

Abstract

Background: Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC). Methods: NT-proBNP was measured after 62 chemotherapy treatments in 52 patients affected by aggressive malignancies. Blood samples were drawn before the start of HDC, at the end of HDC administration, and 12, 24, 36, and 72 h thereafter. In these patients, echocardiograms were performed regularly during a 1-year follow-up. Results: Seventeen patients (33%) had persistently increased NT-proBNP, 19 patients (36%) had only transient increases (concentrations went back to baseline at 72 h), and 16 (31%) had no increases [mean (SD) values at 72 h, 1163 (936) ng/L vs 185 (101) ng/L vs 39 (19) ng/L, respectively; P

Original languageEnglish
Pages (from-to)1405-1410
Number of pages6
JournalClinical Chemistry
Volume51
Issue number8
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Chemotherapy
Brain Natriuretic Peptide
Drug Therapy
Heart Failure
Blood
Neoplasms

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

@article{7ded9267ea9a431f837159b0d4289158,
title = "N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction?",
abstract = "Background: Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC). Methods: NT-proBNP was measured after 62 chemotherapy treatments in 52 patients affected by aggressive malignancies. Blood samples were drawn before the start of HDC, at the end of HDC administration, and 12, 24, 36, and 72 h thereafter. In these patients, echocardiograms were performed regularly during a 1-year follow-up. Results: Seventeen patients (33{\%}) had persistently increased NT-proBNP, 19 patients (36{\%}) had only transient increases (concentrations went back to baseline at 72 h), and 16 (31{\%}) had no increases [mean (SD) values at 72 h, 1163 (936) ng/L vs 185 (101) ng/L vs 39 (19) ng/L, respectively; P",
author = "Sandri, {Maria T.} and Michela Salvatici and Daniela Cardinale and Laura Zorzino and Rita Passerini and Paola Lentati and Maria Leon and Maurizio Civelli and Giovanni Martinelli and Cipolla, {Carlo M.}",
year = "2005",
month = "8",
doi = "10.1373/clinchem.2005.050153",
language = "English",
volume = "51",
pages = "1405--1410",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "8",

}

TY - JOUR

T1 - N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy

T2 - A marker predictive of cardiac dysfunction?

AU - Sandri, Maria T.

AU - Salvatici, Michela

AU - Cardinale, Daniela

AU - Zorzino, Laura

AU - Passerini, Rita

AU - Lentati, Paola

AU - Leon, Maria

AU - Civelli, Maurizio

AU - Martinelli, Giovanni

AU - Cipolla, Carlo M.

PY - 2005/8

Y1 - 2005/8

N2 - Background: Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC). Methods: NT-proBNP was measured after 62 chemotherapy treatments in 52 patients affected by aggressive malignancies. Blood samples were drawn before the start of HDC, at the end of HDC administration, and 12, 24, 36, and 72 h thereafter. In these patients, echocardiograms were performed regularly during a 1-year follow-up. Results: Seventeen patients (33%) had persistently increased NT-proBNP, 19 patients (36%) had only transient increases (concentrations went back to baseline at 72 h), and 16 (31%) had no increases [mean (SD) values at 72 h, 1163 (936) ng/L vs 185 (101) ng/L vs 39 (19) ng/L, respectively; P

AB - Background: Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC). Methods: NT-proBNP was measured after 62 chemotherapy treatments in 52 patients affected by aggressive malignancies. Blood samples were drawn before the start of HDC, at the end of HDC administration, and 12, 24, 36, and 72 h thereafter. In these patients, echocardiograms were performed regularly during a 1-year follow-up. Results: Seventeen patients (33%) had persistently increased NT-proBNP, 19 patients (36%) had only transient increases (concentrations went back to baseline at 72 h), and 16 (31%) had no increases [mean (SD) values at 72 h, 1163 (936) ng/L vs 185 (101) ng/L vs 39 (19) ng/L, respectively; P

UR - http://www.scopus.com/inward/record.url?scp=23044510968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044510968&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2005.050153

DO - 10.1373/clinchem.2005.050153

M3 - Article

C2 - 15932966

AN - SCOPUS:23044510968

VL - 51

SP - 1405

EP - 1410

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 8

ER -